Recognized with brand consultancy is + at in the Best Brand Evolution (Business) and Healthcare and Pharmaceutical Sector visual identity categories
SALT LAKE CITY, October 27, 2026 PolarityBio, a late-stage biotechnology company addressing unmet needs in wound healing through innovation in regenerative multicellular biologics, today announced that it received two honors at the 2026 Transform Awards North America: a Silver award for Best Brand Evolution (Business) and a Bronze award for Best Visual Identity from the Healthcare and Pharmaceutical Sector. Both awards recognize PolarityBio’s work with brand consultancy is + at. Winners were celebrated at the Edison Ballroom in New York City.
Presented by Transform magazine, the Transform Awards North America recognize excellence in rebranding and brand development across the continent. The 2026 program was judged by a panel of experts drawn from organizations including Citi, PwC, Strava and the National Women’s Soccer League.
The recognized work reflects the evolution of the PolarityBio brand as the company positioned around its BLA pathway and introduced a new visual identity.
“As SkinTE® moves through FDA review, our brand has to show clinicians, payers and partners that PolarityBio is a science company pursuing a full Biologics License Application backed by a randomized Phase III program,” said Nikolai Sopko, MD, PhD, Chief Operating Officer and Chief Scientific Officer of PolarityBio. “We’re proud Transform’s judges recognized both our brand evolution and our visual identity, and we thank the team at is + at for their partnership.”
The recognition comes as SkinTE® (autologous cutaneous multicellular units), PolarityBio’s lead product, is under review by the U.S. Food and Drug Administration (FDA). The FDA has accepted PolarityBio’s Biologics License Application (BLA) for SkinTE® for the treatment of Wagner Grade 1 diabetic foot ulcers (DFUs) and granted Priority Review. SkinTE® is investigational and is not approved by the FDA for any indication.
About PolarityBio
PolarityBio, headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative multicellular biologics. PolarityBio’s lead product is SkinTE®, a first-in-class autologous cutaneous multicellular therapy. The FDA has accepted PolarityBio’s Biologics License Application (BLA) for SkinTE® for the treatment of Wagner Grade 1 diabetic foot ulcers (DFUs) and granted Priority Review. The program holds Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations. Beyond DFUs, PolarityBio is advancing SkinTE® for additional chronic wound indications, including venous leg ulcers (VLUs) and pressure injuries. SkinTE® is currently available for investigational use only through an Expanded Access Program.
About the Transform Awards The Transform Awards are organized by Transform magazine, a quarterly print title published by Cravenhill Publishing that covers brand strategy and design. In addition to the magazine and website, Transform runs conferences and awards programs around the world, including the Transform Awards North America. The full list of 2026 North America winners is available at transformmagazine.net.
Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. PolarityBio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Company Contact connect@polaritybio.com
Investor Relations Contact IR@polaritybio.com